- Home
- AMS vs EDSA Comparison
AMS vs EDSA Comparison
Compare AMS & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- EDSA
- Stock Information
- Founded
- AMS 1980
- EDSA 2015
- Country
- AMS United States
- EDSA Canada
- Employees
- AMS N/A
- EDSA N/A
- Industry
- AMS Medical Specialities
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- EDSA Health Care
- Exchange
- AMS Nasdaq
- EDSA Nasdaq
- Market Cap
- AMS 17.2M
- EDSA 17.2M
- IPO Year
- AMS N/A
- EDSA N/A
- Fundamental
- Price
- AMS $2.50
- EDSA $2.39
- Analyst Decision
- AMS
- EDSA Strong Buy
- Analyst Count
- AMS 0
- EDSA 2
- Target Price
- AMS N/A
- EDSA $13.00
- AVG Volume (30 Days)
- AMS 3.7K
- EDSA 11.7K
- Earning Date
- AMS 11-12-2025
- EDSA 08-08-2025
- Dividend Yield
- AMS N/A
- EDSA N/A
- EPS Growth
- AMS N/A
- EDSA N/A
- EPS
- AMS N/A
- EDSA N/A
- Revenue
- AMS $29,251,000.00
- EDSA N/A
- Revenue This Year
- AMS $5.06
- EDSA N/A
- Revenue Next Year
- AMS N/A
- EDSA N/A
- P/E Ratio
- AMS N/A
- EDSA N/A
- Revenue Growth
- AMS 26.61
- EDSA N/A
- 52 Week Low
- AMS $2.27
- EDSA $1.55
- 52 Week High
- AMS $3.59
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- AMS 43.71
- EDSA 51.23
- Support Level
- AMS $2.39
- EDSA $2.35
- Resistance Level
- AMS $2.57
- EDSA $2.47
- Average True Range (ATR)
- AMS 0.07
- EDSA 0.07
- MACD
- AMS -0.01
- EDSA -0.01
- Stochastic Oscillator
- AMS 10.00
- EDSA 31.76
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.